Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.

View Full Paper
Ask AI
Bookmark
Share

Authors

SLShun LuAnhui Sanlian UniversityQZQingyuan ZhangQingdao UniversityXMXiangjiao MengShandong University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lu et al. (2024) studied this question.

synapsesocial.com/papers/68e674e7b6db6435875ff7d5https://doi.org/10.1200/jco.2024.42.16_suppl.e15007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.2024 · 14 citations
  2. 2Abstract 5819: An anti-TROP2-CPT113 ADC, exhibits potent targeted antitumor activity and favorable pharmacokinetic properties2024
  3. 3A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors.2024 · 4 citations
  4. 4Updated efficacy results from the phase I cervical cancer cohort of BAT8008, a TROP-2–directed antibody-drug conjugate, in patients with advanced cervical cancer.2026 · 1 citations
  5. 5A phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors.2024 · 1 citations